FDA snubs Novartis bid to repurpose inflammation drug for heart attacks
The U.S. Food and Drug Administration has rejected Novartis's bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, the Swiss drugmaker said on Thursday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cardiology | Food and Drug Administration (FDA) | Health | Heart | Heart Attack | Switzerland Health